

IDERA PHARMACEUTICALS, INC.

Form 8-K

March 06, 2007

Table of Contents

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549**

**FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934**

Date of Report (Date of earliest event reported): March 6, 2007

Idera Pharmaceuticals, Inc.

(Exact name of Registrant as Specified in Charter)

Delaware

001-31918

04-3072298

(State or Other Jurisdiction
of Incorporation)

(Commission File Number)

(IRS Employer Identification No.)

345 Vassar Street, Cambridge, Massachusetts

02139

(Address of Principal Executive Offices)

(Zip Code)

Registrant's telephone number, including area code: (617) 679-5500

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

TABLE OF CONTENTS

Item 1.01. Entry into a Material Definitive Agreement

Item 2.02. Results of Operation and Financial Condition.

Item 9.01. Financial Statements and Exhibits.

SIGNATURE

Ex-10.1 Exclusive License and Research Collaboration Agreement, dated December 8, 2006.

Ex-99.1 Press release, dated March 6, 2007.

Item 1.01. Entry into a Material Definitive Agreement

On December 11, 2006, Idera Pharmaceuticals, Inc. (Idera) announced that it had entered into an Exclusive License and Research Collaboration Agreement (the Collaboration Agreement) with Merck & Co., Inc. A description of the Collaboration Agreement is contained in the Current Report on Form 8-K filed by Idera with the Securities and Exchange Commission on December 13, 2006. The Collaboration Agreement is being filed as an exhibit to this Current Report on Form 8-K.

Item 2.02. Results of Operation and Financial Condition.

On March 6, 2007, Idera announced its financial results for the quarter and year ended December 31, 2006. The full text of the press release issued in connection with the announcement is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

The information in Item 2.02 of this Form 8-K (including Exhibit 99.1) is being furnished and shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934 (the Exchange Act) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

10.1 Exclusive License and Research Collaboration Agreement dated December 8, 2006 by and between Merck & Co., Inc. and Idera Pharmaceuticals, Inc.

99.1* Press release issued by Idera Pharmaceuticals, Inc. on March 6, 2007.

Confidential treatment has been requested as to certain portions of this Exhibit. Such portions have been omitted and filed separately with the Securities and Exchange Commission.

* Exhibit 99.1 relating to Item 2.02 shall be deemed to be

furnished, and
not filed.

Table of Contents

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

IDERA PHARMACEUTICALS, INC.

Date: March 6, 2007

By: /s/ Robert G. Andersen
Robert G. Andersen
Chief Financial Officer and Vice
President of Operations